Evidence map›Paper›PMID 38416180›Full record

ReviewArchives of microbiology2024

Fighting nature with nature: antiviral compounds that target retroviruses.

Zhen Yun Siew, Elishea Asudas, Chia Ting Khoo, Gang Hyeon Cho, Kenny Voon, Chee-Mun Fang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Anti-HIV Potential ofViruses · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Recent Advances in the Epidemiology of Pathogenic Agents.Pathogens (Basel, Switzerland) · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zhen Yun SiewDivision of Biomedical Sciences, School of Pharmacy, University of Nottingham Malaysia, Jalan Broga, 43500, Semenyih, Selangor, Malaysia. hfyzs1@nottingham.edu.my.
Elishea AsudasDivision of Biomedical Sciences, School of Pharmacy, University of Nottingham Malaysia, Jalan Broga, 43500, Semenyih, Selangor, Malaysia.
Chia Ting KhooSchool of Biosciences, University of Nottingham Malaysia, 43500, Semenyih, Selangor, Malaysia.
Gang Hyeon ChoSchool of Pharmacy, University of Nottingham Malaysia, 43500, Semenyih, Selangor, Malaysia.
Kenny VoonDivision of Biomedical Sciences, School of Pharmacy, University of Nottingham Malaysia, Jalan Broga, 43500, Semenyih, Selangor, Malaysia.
Chee-Mun FangDivision of Biomedical Sciences, School of Pharmacy, University of Nottingham Malaysia, Jalan Broga, 43500, Semenyih, Selangor, Malaysia. cheemun.fang@nottingham.edu.my.
University of Nottingham Malaysia Campus · MY

Funding

University of Nottingham Malaysia Campus F0013.54.04
6 · The paper itself

Abstract

The human immunodeficiency virus (HIV) is a type of lentivirus that targets the human immune system and leads to acquired immunodeficiency syndrome (AIDS) at a later stage. Up to 2021, there are millions still living with HIV and many have lost their lives. To date, many anti-HIV compounds have been discovered in living organisms, especially plants and marine sponges. However, no treatment can offer a complete cure, but only suppressing it with a life-long medication, known as combined antiretroviral therapy (cART) or highly active antiretroviral therapy (HAART) which are often associated with various adverse effects. Also, it takes many years for a discovered compound to be approved for clinical use. Thus, by employing advanced technologies such as automation, conducting systematic screening and testing protocols may boost the discovery and development of potent and curative therapeutics for HIV infection/AIDS. In this review, we aim to summarize the antiretroviral therapies/compounds and their associated drawbacks since the discovery of azidothymidine. Additionally, we aim to provide an updated analysis of the most recent discoveries of promising antiretroviral candidates, along with an exploration of the current limitations within antiretroviral research. Finally, we intend to glean insightful perspectives and propose future research directions in this crucial area of study.

Indexed as

HIV InfectionsPoriferaAnimalsAntiviral AgentsData CollectionHumansRetroviridaeAntiviral AgentsAcquired immunodeficiency syndromeAntiretroviral compoundBioactive constituentCureHuman immunodeficiency virusRetrovirus

Identifiers

PMID38416180
OpenAlexW4392240930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.